Ovid Therapeutics Inc. (OVID) stock
OVIDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 10/30
$2.22−0.18 (-7.50%)
Close on Nov 17, 2026Market cap $433.56MP/E –Yield –
Ovid Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Ovid Therapeutics's total assets was $231.97M at Jun 30, 2026. For fiscal 2025 it was $150.93M, up 63.8% from the year before. The highest annual figure on record is $194.54M in fiscal 2021.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $150.93M | +63.8% |
| FY2024 | Dec 31, 2024 | $92.17M | -36.0% |
| FY2023 | Dec 31, 2023 | $144.03M | -7.2% |
| FY2022 | Dec 31, 2022 | $155.27M | -20.2% |
| FY2021 | Dec 31, 2021 | $194.54M | +156.2% |
| FY2020 | Dec 31, 2020 | $75.93M | -6.1% |
| FY2019 | Dec 31, 2019 | $80.84M | +69.7% |
| FY2018 | Dec 31, 2018 | $47.65M | -46.7% |
| FY2017 | Dec 31, 2017 | $89.46M | +68.7% |
| FY2016 | Dec 31, 2016 | $53.03M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $231.97M | +199.6% |
| Q1 FY2026 | Mar 31, 2026 | $225.63M | +176.3% |
| Q4 FY2025 | Dec 31, 2025 | $150.93M | +63.8% |
| Q3 FY2025 | Sep 30, 2025 | $63.85M | -37.8% |
| Q2 FY2025 | Jun 30, 2025 | $77.43M | -34.4% |
| Q1 FY2025 | Mar 31, 2025 | $81.65M | -38.0% |
| Q4 FY2024 | Dec 31, 2024 | $92.17M | -36.0% |
| Q3 FY2024 | Sep 30, 2024 | $102.65M | -17.9% |
| Q2 FY2024 | Jun 30, 2024 | $118.09M | -13.3% |
| Q1 FY2024 | Mar 31, 2024 | $131.61M | -8.2% |
| Q4 FY2023 | Dec 31, 2023 | $144.03M | -7.2% |
| Q3 FY2023 | Sep 30, 2023 | $125.03M | -24.2% |
| Q2 FY2023 | Jun 30, 2023 | $136.23M | -23.2% |
| Q1 FY2023 | Mar 31, 2023 | $143.37M | -25.0% |
| Q4 FY2022 | Dec 31, 2022 | $155.27M | -20.2% |
| Q3 FY2022 | Sep 30, 2022 | $165.03M | -20.3% |
| Q2 FY2022 | Jun 30, 2022 | $177.33M | -18.7% |
| Q1 FY2022 | Mar 31, 2022 | $191.10M | -19.5% |
| Q4 FY2021 | Dec 31, 2021 | $194.54M | +156.2% |
| Q3 FY2021 | Sep 30, 2021 | $207.09M | +126.1% |
| Q2 FY2021 | Jun 30, 2021 | $218.00M | +380.6% |
| Q1 FY2021 | Mar 31, 2021 | $237.46M | +284.7% |
| Q4 FY2020 | Dec 31, 2020 | $75.93M | -6.1% |
| Q3 FY2020 | Sep 30, 2020 | $91.60M | +125.1% |
| Q2 FY2020 | Jun 30, 2020 | $45.36M | -17.4% |
| Q1 FY2020 | Mar 31, 2020 | $61.72M | -7.4% |
| Q4 FY2019 | Dec 31, 2019 | $80.84M | +69.7% |
| Q3 FY2019 | Sep 30, 2019 | $40.69M | -32.6% |
| Q2 FY2019 | Jun 30, 2019 | $54.91M | -20.0% |
| Q1 FY2019 | Mar 31, 2019 | $66.66M | -15.3% |
| Q4 FY2018 | Dec 31, 2018 | $47.65M | -46.7% |
| Q3 FY2018 | Sep 30, 2018 | $60.39M | -38.1% |
| Q2 FY2018 | Jun 30, 2018 | $68.61M | -36.5% |
| Q1 FY2018 | Mar 31, 2018 | $78.67M | +66.7% |
| Q4 FY2017 | Dec 31, 2017 | $89.46M | +68.7% |
| Q3 FY2017 | Sep 30, 2017 | $97.57M | – |
| Q2 FY2017 | Jun 30, 2017 | $108.01M | – |
| Q1 FY2017 | Mar 31, 2017 | $47.20M | – |
| Q4 FY2016 | Dec 31, 2016 | $53.03M | – |
See a number that looks wrong?